These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
634 related articles for article (PubMed ID: 16467864)
1. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864 [TBL] [Abstract][Full Text] [Related]
2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. Harada Y; Harada H J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations. Harada Y; Harada H J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063 [TBL] [Abstract][Full Text] [Related]
4. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072 [TBL] [Abstract][Full Text] [Related]
5. AML1/RUNX1 gene point mutations in childhood myeloid malignancies. Migas A; Savva N; Mishkova O; Aleinikova OV Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243 [TBL] [Abstract][Full Text] [Related]
6. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome. Harada H; Harada Y Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315 [TBL] [Abstract][Full Text] [Related]
7. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients. Roumier C; Lejeune-Dumoulin S; Renneville A; Goethgeluck AS; Philippe N; Fenaux P; Preudhomme C Leukemia; 2006 Mar; 20(3):433-6. PubMed ID: 16424869 [TBL] [Abstract][Full Text] [Related]
8. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS. Harada H; Harada Y; Kimura A Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876 [TBL] [Abstract][Full Text] [Related]
9. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860 [TBL] [Abstract][Full Text] [Related]
10. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365 [TBL] [Abstract][Full Text] [Related]
12. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations]. Harada H Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302 [No Abstract] [Full Text] [Related]
13. Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations. Christiansen DH; Desta F; Andersen MK; Pedersen-Bjergaard J Genes Chromosomes Cancer; 2007 Jun; 46(6):517-21. PubMed ID: 17330262 [TBL] [Abstract][Full Text] [Related]
15. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630 [TBL] [Abstract][Full Text] [Related]
16. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106 [TBL] [Abstract][Full Text] [Related]
17. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077 [TBL] [Abstract][Full Text] [Related]
18. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases. Ghaddar HM; Stass SA; Pierce S; Estey EH Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160 [TBL] [Abstract][Full Text] [Related]
19. New mechanisms of AML1 gene alteration in hematological malignancies. Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]